Dayton Misfeldt is a Managing Director of Bay City Capital and has been with the firm since 2000. He invests primarily in companies developing biopharmaceutical products and works closely with management teams with an eye toward strategic decision making, business development, and positioning for exit opportunities through accessing public markets or acquisition. He brings significant capital markets expertise and financial sophistication to his investments supported by industry experience spanning two decades and multiple market cycles.
Mr. Misfeldt currently serves on the boards of directors of Interleukin Genetics, Sunesis Pharmaceuticals, and Tria Beauty. Past successes have included Cadence Pharmaceuticals, MAP Pharmaceuticals, Nextwave Pharmaceuticals, Oculex Pharmaceuticals, and Pharmion Corporation.
Prior to joining Bay City Capital, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. He began his career at LifeScience Economics. Mr. Misfeldt received a BA in Economics from the University of California, San Diego.